Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

PBD Biotech secures grant of key patent for new bacterial diagnostic technology

PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.
  • October 25, 2018
  • Company
Bacteria

This patent covers the Actiphage® technology that allows the sensitive and specific detection of live bacteria within a few hours. Currently applied to the detection of mycobacterial diseases in animals such as Bovine Tuberculosis (TB) and Johne’s Disease, the technology is also applicable to human infections including other bacterial families.

Dr Berwyn Clarke, PBD Biotech’s Chief Executive Officer, comments, “The technology has already been successfully applied for analysis of blood and milk and, for the first time, gives a realistic alternative to culture but within 6 to 8 hours rather than many weeks. Having the patent granted for the Actiphage Rapid technology is a major milestone for the company and allows us to confidently pursue our commercialisation plans in Europe and internationally.”

Mycobacterial infection is responsible for several chronic diseases worldwide and existing diagnostics are limited by sensitivity, accuracy and speed of delivering reliable results.

Earlier this year, the UK Government Animal and Plant Health Agency (APHA) approved Actiphage for exceptional private use in farms where there is chronic infection of bovine TB. This followed a successful on-farm demonstration, which used Actiphage to provide early identification of affected cows as part of a successful disease management strategy.

Dr Clarke continues: “Grant of the European patent strengthens our belief in the uniqueness of this test, and also ensures that our investment in further developing this technology for other applications is safeguarded.”

Share:

Related posts

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as Director of Operations in North America, to advise on regulatory affairs and provide technical and customer support.
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
1 2 … 5 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More